Advertisement
NEO vs RVTY
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NEO is a Hold and RVTY is a Hold.
NEO's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for NEO turned positive on October 27, 2026. Looking at past instances where NEO's MACD turned positive, the stock continued to rise in 42 of 48 cases over the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on NEO as a result. In 68 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
Following a +4.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where NEO advanced for three days, in 216 of 278 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 55 cases where NEO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 78%.
NEO moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for NEO crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 64%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NEO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
NEO broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.754) is normal, around the industry mean (67.298). P/E Ratio (-43.179) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.060) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (3.189) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. NEO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 71 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NEO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
Momentum Indicator for RVTY turns negative, indicating new downward trend
RVTY saw its Momentum Indicator move below the 0 level on November 05, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 88 similar instances where the indicator turned negative. In 62 of the 88 cases, the stock moved further down in the following days. The odds of a decline are at 70%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for RVTY moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 21 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 68%.
The Moving Average Convergence Divergence Histogram (MACD) for RVTY turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 29 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 60%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RVTY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
RVTY broke above its upper Bollinger Band on October 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +2.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where RVTY advanced for three days, in 200 of 300 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
The Aroon Indicator entered an Uptrend today. In 112 of 186 cases where RVTY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 60%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 3 (best 1 - 100 worst), indicating outstanding price growth. RVTY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.394) is normal, around the industry mean (67.298). P/E Ratio (74.572) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.734) is also within normal values, averaging (3.473). Dividend Yield (0.002) settles around the average of (0.002) among similar stocks. P/S Ratio (5.656) is also within normal values, averaging (9.775).
The Tickeron SMR rating for this company is 86 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RVTY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
NEO | RVTY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 27 Undervalued | 79 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 92 | 86 | |
PRICE GROWTH RATING 1..100 | 36 | 3 | |
P/E GROWTH RATING 1..100 | 71 | 8 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NEO's Valuation (27) in the Medical Or Nursing Services industry is somewhat better than the same rating for RVTY (79) in the Medical Specialties industry. This means that NEO’s stock grew somewhat faster than RVTY’s over the last 12 months.
NEO's Profit vs Risk Rating (100) in the Medical Or Nursing Services industry is in the same range as RVTY (100) in the Medical Specialties industry. This means that NEO’s stock grew similarly to RVTY’s over the last 12 months.
RVTY's SMR Rating (86) in the Medical Specialties industry is in the same range as NEO (92) in the Medical Or Nursing Services industry. This means that RVTY’s stock grew similarly to NEO’s over the last 12 months.
RVTY's Price Growth Rating (3) in the Medical Specialties industry is somewhat better than the same rating for NEO (36) in the Medical Or Nursing Services industry. This means that RVTY’s stock grew somewhat faster than NEO’s over the last 12 months.
RVTY's P/E Growth Rating (8) in the Medical Specialties industry is somewhat better than the same rating for NEO (71) in the Medical Or Nursing Services industry. This means that RVTY’s stock grew somewhat faster than NEO’s over the last 12 months.
| NEO | RVTY | |
|---|---|---|
| RSI ODDS (%) | N/A | 4 days ago 68% |
| Stochastic ODDS (%) | 4 days ago 78% | 4 days ago 70% |
| Momentum ODDS (%) | 4 days ago 80% | 4 days ago 70% |
| MACD ODDS (%) | 4 days ago 88% | 4 days ago 60% |
| TrendWeek ODDS (%) | 4 days ago 80% | 4 days ago 67% |
| TrendMonth ODDS (%) | 4 days ago 80% | 4 days ago 66% |
| Advances ODDS (%) | 6 days ago 78% | 12 days ago 67% |
| Declines ODDS (%) | 8 days ago 81% | 5 days ago 67% |
| BollingerBands ODDS (%) | 4 days ago 73% | 4 days ago 64% |
| Aroon ODDS (%) | N/A | 4 days ago 60% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NEO’s FA Score shows that 1 FA rating(s) are green while RVTY’s FA Score has 2 green FA rating(s).
- NEO’s FA Score: 1 green, 4 red.
- RVTY’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NEO’s TA Score shows that 3 TA indicator(s) are bullish while RVTY’s TA Score has 3 bullish TA indicator(s).
- NEO’s TA Score: 3 bullish, 5 bearish.
- RVTY’s TA Score: 3 bullish, 5 bearish.
Price Growth
NEO (@Medical Specialties) experienced а -3.11% price change this week, while RVTY (@Medical Specialties) price change was -1.20% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -1.03%. For the same industry, the average monthly price growth was -5.12%, and the average quarterly price growth was +40.45%.
Reported Earning Dates
NEO is expected to report earnings on Feb 23, 2027.
RVTY is expected to report earnings on Feb 04, 2027.
Industries' Descriptions
@Medical Specialties (-1.03% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement